@article{HuLinnerTrummeretal., author = {Hu, Rongbo and Linner, Thomas and Trummer, Julian and G{\"u}ttler, J{\"o}rg and Kabouteh, Amir and Langosch, Katharina and Bock, Thomas}, title = {Developing a Smart Home Solution Based on Personalized Intelligent Interior Units to Promote Activity and Customized Healthcare for Aging Society}, series = {Journal of Population Ageing: Special Issue on responsive engagement of older persons promoting activity and customized healthcare}, volume = {13}, journal = {Journal of Population Ageing: Special Issue on responsive engagement of older persons promoting activity and customized healthcare}, number = {1}, publisher = {Springer Nature}, doi = {10.1007/s12062-020-09267-6}, pages = {257 -- 280}, abstract = {The world's population is aging at an unprecedented pace. Aging society is not only a severe crisis in the developed world, but also a rigorous challenge in emerging economies. Many age-related diseases are fostered by the lack of physical, cognitive, and social activities. Increasing the activity level has many benefits for the elderly and can improve their independence. Based on the analysis of the state-of-the-art and shortcomings of the current smart home solutions, the EU-funded research project REACH aims to develop a service system that will turn clinical and care environments into personalized modular sensing, prevention, and intervention systems that encourage the elderly to become healthy through various activities. To achieve that goal, the research team developed a series of smart furniture (PI2Us) that materialize the research concepts and functionality seamlessly into the various environments. Specifically, the development process and the functionality testing results of the PI2Us are reported in detail. In addition, a simulated smart home solution concept (TRACK) integrating key assistive technologies developed is proposed to create a comprehensive interior living and care environment for elderly users. Due to its modularity and flexibility, the partial or entire solution can be easily adapted and rapidly deployed in different use case settings in Europe, which allows the project consortium to execute different testing activities. In the next phase, the research team will focus on enhancing the usability and performance of the prototypes in order to eventually push them to the market. In conclusion, this research provides an innovative smart home solution for the industry to mitigate the impact of aging society.}, language = {en} } @article{WesselyHausleiterMichaelisetal., author = {Wessely, Rainer and Hausleiter, J{\"o}rg and Michaelis, Cornelia and Jaschke, Birgit and Vogeser, Michael and Milz, Stefan and Behnisch, Boris and Schratzenstaller, Thomas and Renke-Gluszko, Magdalena and St{\"o}ver, Michael and Wintermantel, Erich and Kastrati, Adnan and Sch{\"o}mig, Albert}, title = {Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating}, series = {Arteriosclerosis, Thrombosis, and Vascular Biology}, volume = {25}, journal = {Arteriosclerosis, Thrombosis, and Vascular Biology}, number = {4}, issn = {1524-4636}, doi = {10.1161/01.ATV.0000157579.52566.ee}, pages = {748 -- 753}, abstract = {Objective The risk of in-stent restenosis can be considerably reduced by stents eluting cytostatic compounds. We created a novel drug-eluting stent system that includes several new features in the rapidly evolving field of stent-based drug delivery. Methods and Results The aim of the present study was the preclinical evaluation of a stent-coating system permitting individual, on-site coating of stents with a unique microporous surface allowing for individualizable, dose-adjustable, and multiple coatings with identical or various compounds, designated ISAR (individualizable drug-eluting stent system to abrogate restenosis). Stents were coated with 0.75\% rapamycin solution, and high-performance liquid chromatography (HPLC)-based determination of drug release profile indicated drug release for >21 days. Rapamycin-eluting microporous (REMP) stents implanted in porcine coronary arteries were safe. To determine the efficacy of REMP stents, this novel drug-eluting stent platform was compared with the standard sirolimus-eluting stent. At 30 days, in-stent neointima formation in porcine coronary arteries was similar in both groups, yielding a significant decrease of neointimal area and injury-dependent neointimal thickness compared with bare-metal stents. Conclusion The ISAR drug-eluting stent platform as a novel concept for stent coating allows for a safe, effective, on-site stent coating process, thus justifying further clinical evaluation to decrease in-stent restenosis in humans. In-stent neointima formation can be successfully attenuated by drug-eluting stents. We introduce a novel conceptual approach for stent-coating that allows for dose-adjustable, on-site stent coating process if desired with multiple compounds. Microporous stents coated with rapamycin proved safe and effective for the limitation of neointima formation in a porcine coronary stent model.}, language = {en} } @article{HausleiterKastratiWesselyetal., author = {Hausleiter, J{\"o}rg and Kastrati, Adnan and Wessely, Rainer and Dibra, Alban and Mehilli, Julinda and Schratzenstaller, Thomas and Graf, Isolde and Renke-Gluszko, Magdalena and Behnisch, Boris and Dirschinger, Josef and Wintermantel, Erich and Sch{\"o}mig, Albert}, title = {Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating}, series = {European Heart Journal - Clinical research}, volume = {26}, journal = {European Heart Journal - Clinical research}, number = {15}, doi = {10.1093/eurheartj/ehi405}, pages = {1475 -- 1481}, abstract = {Aims Drug-eluting stents (DES) represent a major advance in interventional cardiology. Along with the success shown, current DES also present limitations related to the presence of polymer-coating, fixed drug, and dose used. With the ISAR (Individualized Drug-Eluting Stent System to Abrogate Restenosis) project, a DES system has been developed that permits individualized choice of the drug and dose to use for the given patient. The objective of this prospective dose finding study was to assess the feasibility, safety, and efficacy of a polymer-free on-site stent coating with increasing rapamycin doses. Methods and results In this dose finding study, 602 patients were sequentially enrolled in four groups: microporous bare metal stent (BMS), DES stents coated with a 0.5, 1.0, and 2.0\% rapamycin solution. The angiographic in-segment restenosis rate at follow-up angiography was the primary study endpoint. In-segment restenosis was significantly reduced from 25.9\% with BMS to 18.9, 17.2, and 14.7\% with 0.5, 1.0, and 2.0\% rapamycin-eluting stents, respectively (P=0.024). Similarly, the need for target lesion revascularization at 1 year follow-up was reduced from 21.5\% with BMS to 16.4, 12.6, and 8.8\% with 0.5, 1.0, and 2.0\% rapamycin-eluting stents, respectively (P=0.006). Conclusion The placement of polymer-free stents coated on-site with rapamycin is feasible and safe. Furthermore, a dose-dependent efficacy in restenosis prevention is achievable with this new DES concept.}, language = {en} } @article{SchildgenJoergDossingeretal., author = {Schildgen, Johannes and J{\"o}rg, Thomas and Dossinger, Manuel and Deßloch, Stefan}, title = {Marimba: A framework for making MapReduce jobs incremental}, series = {Proceedings - 2014 IEEE International Congress on Big Data, BigData Congress 2014, 27 June 2014 - 02 July 2014, Anchorage, AK, USA}, journal = {Proceedings - 2014 IEEE International Congress on Big Data, BigData Congress 2014, 27 June 2014 - 02 July 2014, Anchorage, AK, USA}, publisher = {IEEE}, doi = {10.1109/BigData.Congress.2014.27}, abstract = {Many MapReduce jobs for analyzing Big Data require many hours and have to be repeated again and again because the base data changes continuously. In this paper we propose Marimba, a framework for making MapReduce jobs incremental. Thus, a recomputation of a job only needs to process the changes since the last computation. This accelerates the execution and enables more frequent recomputations, which leads to results which are more up-to-date. Our approach is based on concepts that are popular in the area of materialized views in relational database systems where a view can be updated only by aggregating changes in base data upon the previous result.}, language = {en} }